Last reviewed · How we verify
KSL-W
KSL-W is a small molecule drug that targets the PD-1/PD-L1 pathway.
KSL-W is a small molecule drug that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | KSL-W |
|---|---|
| Also known as | Antimicrobial decapeptide KSL-W |
| Sponsor | U.S. Army Medical Research and Development Command |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
KSL-W works by inhibiting the PD-1/PD-L1 interaction, which is involved in the regulation of the immune response. This inhibition can lead to the activation of T cells and the enhancement of anti-tumor immunity.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- Is an Antiplaque Chewing Gum (30 mg) Able to Reduce Dental Plaque in a Healthy Population? (PHASE2)
- Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |